

# Francesco Bertolini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/315893/publications.pdf>

Version: 2024-02-01

245  
papers

12,007  
citations

25014

57  
h-index

30894

102  
g-index

256  
all docs

256  
docs citations

256  
times ranked

12759  
citing authors

#	ARTICLE	IF	CITATIONS
1	The multifaceted circulating endothelial cell in cancer: towards marker and target identification. <i>Nature Reviews Cancer</i> , 2006, 6, 835-845.	12.8	559
2	Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents. <i>Cancer Cell</i> , 2008, 14, 263-273.	7.7	424
3	Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. <i>Blood</i> , 2001, 97, 3658-3661.	0.6	401
4	Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. <i>Cancer Research</i> , 2003, 63, 4342-6.	0.4	375
5	Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings. <i>Journal of Clinical Oncology</i> , 2002, 20, 4169-4180.	0.8	361
6	Circulating endothelial cells. <i>Thrombosis and Haemostasis</i> , 2005, 93, 228-235.	1.8	337
7	Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis. <i>Cancer Cell</i> , 2005, 7, 101-111.	7.7	332
8	Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4899-4905.	0.8	280
9	Angiogenesis in myelodysplastic syndromes. <i>British Journal of Cancer</i> , 1999, 81, 1398-1401.	2.9	260
10	Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. <i>Blood</i> , 2005, 106, 3058-3061.	0.6	252
11	Drug repurposing in oncology—patient and health systems opportunities. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 732-742.	12.5	247
12	Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. <i>Blood</i> , 2006, 108, 452-459.	0.6	242
13	Locoregional recurrence risk after lipofilling in breast cancer patients. <i>Annals of Oncology</i> , 2012, 23, 582-588.	0.6	203
14	Megakaryocytic Progenitors Can Be Generated Ex Vivo and Safely Administered to Autologous Peripheral Blood Progenitor Cell Transplant Recipients. <i>Blood</i> , 1997, 89, 2679-2688.	0.6	177
15	In Vitro Assessment of the Quality of Stored Platelet Concentrates. <i>Transfusion Medicine Reviews</i> , 1994, 8, 29-36.	0.9	176
16	Evaluation of fat grafting safety in patients with intra epithelial neoplasia: a matched-cohort study. <i>Annals of Oncology</i> , 2013, 24, 1479-1484.	0.6	172
17	CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. <i>Cancer Research</i> , 2002, 62, 3106-12.	0.4	166
18	Human acute leukemia cells injected in NOD/LtSz-IL2R <sup>0</sup> null mice generate a faster and more efficient disease compared to other NOD-related strains. <i>International Journal of Cancer</i> , 2008, 123, 2222-2227.	2.3	155

#	ARTICLE	IF	CITATIONS
19	Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses. <i>Clinical Cancer Research</i> , 2009, 15, 267-273.	3.2	153
20	Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1999, 106, 504-509.	1.2	151
21	The White Adipose Tissue Used in Lipotransfer Procedures Is a Rich Reservoir of CD34+ Progenitors Able to Promote Cancer Progression. <i>Cancer Research</i> , 2012, 72, 325-334.	0.4	138
22	The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. <i>International Journal of Cancer</i> , 2015, 136, E534-44.	2.3	119
23	Paradoxical effects of metformin on endothelial cells and angiogenesis. <i>Carcinogenesis</i> , 2014, 35, 1055-1066.	1.3	118
24	Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies. <i>Cancer Research</i> , 2011, 71, 1362-1373.	0.4	117
25	Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. <i>Blood</i> , 2004, 104, 1662-1670.	0.6	111
26	High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 5190-5198.	3.2	106
27	Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. <i>Clinical Cancer Research</i> , 2009, 15, 7652-7657.	3.2	102
28	Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice. <i>Cancer Research</i> , 2011, 71, 6986-6996.	0.4	102
29	Evaluation of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. <i>Transfusion</i> , 1989, 29, 605-609.	0.8	101
30	A multicenter inspection of the swirling phenomenon in platelet concentrates prepared in routine practice. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. <i>Transfusion</i> , 1996, 36, 128-132.	0.8	100
31	Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. <i>Clinical Cancer Research</i> , 2003, 9, 377-82.	3.2	99
32	The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. <i>Blood</i> , 2007, 109, 533-542.	0.6	93
33	Complementary Populations of Human Adipose CD34+ Progenitor Cells Promote Growth, Angiogenesis, and Metastasis of Breast Cancer. <i>Cancer Research</i> , 2013, 73, 5880-5891.	0.4	91
34	Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. <i>British Journal of Haematology</i> , 2002, 118, 817-820.	1.2	87
35	Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. <i>Blood</i> , 2000, 96, 282-287.	0.6	84
36	Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. <i>Breast</i> , 2005, 14, 466-479.	0.9	84

#	ARTICLE	IF	CITATIONS
37	Molecular and cellular biomarkers for angiogenesis in clinical oncology. <i>Drug Discovery Today</i> , 2007, 12, 806-812.	3.2	84
38	Assessing Tumor Angiogenesis. <i>Cancer Research</i> , 2004, 64, 4373-4377.	0.4	83
39	Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases. <i>Cell Reports</i> , 2017, 19, 774-784.	2.9	82
40	Circulating Endothelial Cells as a Novel Marker of Angiogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2003, 522, 83-97.	0.8	82
41	Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. <i>Annals of Oncology</i> , 2001, 12, 987-990.	0.6	81
42	Stem cells from adipose tissue and breast cancer: hype, risks and hope. <i>British Journal of Cancer</i> , 2015, 112, 419-423.	2.9	81
43	Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents. <i>Cancer Research</i> , 2009, 69, 7524-7528.	0.4	78
44	The thin red line. <i>Experimental Hematology</i> , 2000, 28, 993-1000.	0.2	77
45	Comparative Study of Different Procedures for the Collection and Banking of Umbilical Cord Blood. <i>Stem Cells and Development</i> , 1995, 4, 29-36.	1.0	76
46	Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. <i>British Journal of Cancer</i> , 2018, 118, 1329-1336.	2.9	75
47	Autologous Peripheral Blood Stem Cell Transplantation for Myocardial Regeneration: A Novel Strategy for Cell Collection and Surgical Injection. <i>Annals of Thoracic Surgery</i> , 2004, 78, 1808-1812.	0.7	73
48	Removal of white cells from red cells by transfusion through a new filter. <i>Transfusion</i> , 1990, 30, 30-33.	0.8	71
49	A multicenter evaluation of reproducibility of swirling in platelet concentrates. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. <i>Transfusion</i> , 1994, 34, 796-801.	0.8	71
50	Leukocyte depletion of red cell units at the bedside by transfusion through a new filter. <i>Transfusion</i> , 1987, 27, 402-405.	0.8	70
51	Role of acetate during platelet storage in a synthetic medium. <i>Transfusion</i> , 1992, 32, 152-156.	0.8	70
52	Fat Grafting after Invasive Breast Cancer: A Matched Case-Control Study. <i>Plastic and Reconstructive Surgery</i> , 2017, 139, 1292-1296.	0.7	70
53	Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. <i>Laboratory Investigation</i> , 2012, 92, 952-966.	1.7	65
54	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34 <sup>+</sup> cell population with intrinsic resistance to imatinib. <i>Blood</i> , 2009, 114, 5191-5200.	0.6	62

#	ARTICLE	IF	CITATIONS
55	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151.	0.9	61
56	Adipose Progenitor Cell Secretion of GM-CSF and MMP9 Promotes a Stromal and Immunological Microenvironment That Supports Breast Cancer Progression. <i>Cancer Research</i> , 2017, 77, 5169-5182.	0.4	60
57	Red cellâ€bound antibodies and transfusion requirements in hospitalized patients with COVID-19. <i>Blood</i> , 2020, 136, 766-768.	0.6	60
58	Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF-Î²) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 35-40.	1.1	59
59	Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity. <i>Clinical Breast Cancer</i> , 2012, 12, 207-214.	1.1	59
60	Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. <i>Haematologica</i> , 2019, 104, 729-737.	1.7	58
61	Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. <i>Drug Discovery Today</i> , 2013, 18, 193-201.	3.2	57
62	Rituximab and Subcutaneous 2-Chloro-2â€Deoxyadenosine Combination Treatment for Patients With WaldenstrÃ¶m Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2233-2238.	0.8	56
63	Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2011, 6, e21369.	1.1	56
64	Skeletal muscle differentiation potential of human adult bone marrow cells. <i>Experimental Cell Research</i> , 2004, 295, 66-78.	1.2	54
65	White cell-reduced red cells prepared by filtration: a critical evaluation of current filters and methods for counting residual white cells. <i>Transfusion</i> , 1993, 33, 128-133.	0.8	52
66	Platelet quality after 15-day storage of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. <i>Transfusion</i> , 1992, 32, 9-16.	0.8	51
67	Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, E54; author reply E55.	3.3	51
68	Circulating endothelial cells as biomarkers in clinical oncology. <i>Microvascular Research</i> , 2010, 79, 224-228.	1.1	50
69	Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 718-725.	2.2	50
70	Preparation of Leukocyteâ€Free Platelets for Transfusion by Filtration through Cotton Wool. <i>Vox Sanguinis</i> , 1983, 44, 115-120.	0.7	48
71	Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose. <i>Current Cancer Drug Targets</i> , 2005, 5, 551-559.	0.8	48
72	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cellsâ€™ vulnerability to DNA-damaging agents. <i>Haematologica</i> , 2018, 103, 80-90.	1.7	48

#	ARTICLE	IF	CITATIONS
73	Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors. <i>Theranostics</i> , 2018, 8, 3856-3869.	4.6	48
74	Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 133-139.	1.0	47
75	Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. <i>Scientific Reports</i> , 2016, 6, 18673.	1.6	46
76	Adipose tissue cells, lipotransfer and cancer: A challenge for scientists, oncologists and surgeons. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 209-214.	3.3	45
77	Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. <i>Oncotarget</i> , 2017, 8, 5895-5908.	0.8	45
78	Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma. <i>Leukemia</i> , 2000, 14, 1477-1482.	3.3	44
79	Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. <i>British Journal of Cancer</i> , 2008, 99, 1564-1571.	2.9	43
80	Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production. <i>EBioMedicine</i> , 2016, 3, 43-53.	2.7	41
81	Stromal Cell-Derived Factor-1 $\alpha$ Promotes Endothelial Colony-Forming Cell Migration Through the Ca <sup>2+</sup> -Dependent Activation of the Extracellular Signal-Regulated Kinase 1/2 and Phosphoinositide 3-Kinase/AKT Pathways. <i>Stem Cells and Development</i> , 2018, 27, 23-34.	1.1	41
82	Safety of Lipofilling in Patients with Breast Cancer. <i>Clinics in Plastic Surgery</i> , 2015, 42, 339-344.	0.7	40
83	Retrovirus-mediated transfer of the multidrug resistance gene into human haemopoietic progenitor cells. <i>British Journal of Haematology</i> , 1994, 88, 318-324.	1.2	39
84	The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. <i>Journal of Pathology</i> , 2005, 206, 337-345.	2.1	39
85	Miniaturized FISH for screening of onco-hematological malignancies. <i>BioTechniques</i> , 2010, 49, 497-504.	0.8	39
86	Circulating endothelial progenitors are increased in COVID-19 patients and correlate with SARS-CoV-2 RNA in severe cases. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2744-2750.	1.9	39
87	Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2005, 46, 1345-1351.	0.6	38
88	Mitochondrial Complex I activity signals antioxidant response through ERK5. <i>Scientific Reports</i> , 2018, 8, 7420.	1.6	38
89	Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer. <i>Drug Discovery Today</i> , 2011, 16, 1052-1060.	3.2	35
90	In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue. <i>Experimental Hematology</i> , 2002, 30, 905-914.	0.2	34

#	ARTICLE	IF	CITATIONS
91	miRNAs Expression Analysis in Paired Fresh/Frozen and Dissected Formalin Fixed and Paraffin Embedded Glioblastoma Using Real-Time PCR. PLoS ONE, 2012, 7, e35596.	1.1	34
92	The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia. Leukemia, 2018, 32, 911-919.	3.3	34
93	Therapeutic Effect of Lenalidomide in a Novel Xenograft Mouse Model of Human Blastic NK Cell Lymphoma/Blastic Plasmacytoid Dendritic Cell Neoplasm. Clinical Cancer Research, 2011, 17, 6163-6173.	3.2	33
94	Multilineage Long-Term Engraftment Potential of Drug-Resistant Hematopoietic Progenitors. Blood, 1997, 90, 3027-3036.	0.6	32
95	Role of Lactate in Platelet Storage Lesion. Vox Sanguinis, 1993, 65, 194-198.	0.7	31
96	Functional and Morphological Characterization of Immunomagnetically Selected CD34 <sup>+</sup> Hematopoietic Progenitor Cells. Stem Cells, 1996, 14, 430-438.	1.4	31
97	Cyclophosphamide and Vinorelbine Activate Stem-Like CD8 <sup>+</sup> T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 685-697.	0.4	31
98	Comparison of Platelet Activation and Membrane Glycoprotein Ib and IIb-IIIa Expression after Filtration through Three Different Leukocyte Removal Filters. Vox Sanguinis, 1990, 59, 201-204.	0.7	30
99	Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. British Journal of Haematology, 2003, 123, 271-277.	1.2	30
100	The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias. Molecular Cancer Therapeutics, 2015, 14, 889-898.	1.9	30
101	Archaeogenomic distinctiveness of the Isthmo-Colombian area. Cell, 2021, 184, 1706-1723.e24.	13.5	30
102	Epithelial tumour cell detection and the unsolved problems of nested RT-PCR: a new sensitive one step method without false positive results. Bone Marrow Transplantation, 1998, 22, 693-698.	1.3	29
103	Prognostic Value of CD109 <sup>+</sup> Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan. PLoS ONE, 2013, 8, e74345.	1.1	28
104	The pan-class I phosphatidylinositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. Scientific Reports, 2015, 5, 18137.	1.6	28
105	The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism. Oncotarget, 2015, 6, 19228-19245.	0.8	28
106	Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. International Journal of Cancer, 2001, 92, 666-670.	2.3	27
107	ecancermedalscience. Ecanermedalscience, 2014, 8, 463.	0.6	26
108	Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. British Journal of Haematology, 2004, 124, 289-298.	1.2	26



#	ARTICLE	IF	CITATIONS
109	A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2146-2154.	3.2	26
110	Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. <i>Breast</i> , 2012, 21, 309-313.	0.9	25
111	Crystallin is a bcl-2 mRNA binding protein involved in bcl-2 overexpression in T-cell acute lymphocytic leukemia. <i>FASEB Journal</i> , 2010, 24, 1852-1865.	0.2	24
112	Spontaneous Cell Fusion of Acute Leukemia Cells and Macrophages Observed in Cells with Leukemic Potential. <i>Neoplasia</i> , 2012, 14, 1057-1064.	2.3	24
113	Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer. <i>British Journal of Cancer</i> , 1997, 75, 1368-1372.	2.9	23
114	Chimerism of the Transplanted Heart. <i>New England Journal of Medicine</i> , 2002, 346, 1410-1412.	13.9	23
115	Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. <i>BJU International</i> , 2008, 101, 884-888.	1.3	23
116	In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels. <i>Leukemia</i> , 2011, 25, 733-736.	3.3	23
117	The PDK1 Inhibitor Dichloroacetate Controls Cholesterol Homeostasis Through the ERK5/MEF2 Pathway. <i>Scientific Reports</i> , 2017, 7, 10654.	1.6	23
118	EPO Receptor Gain-of-Function Causes Hereditary Polycythemia, Alters CD34+ Cell Differentiation and Increases Circulating Endothelial Precursors. <i>PLoS ONE</i> , 2010, 5, e12015.	1.1	23
119	Human Haemato-Endothelial Precursors: Cord Blood CD34+ Cells Produce Haemogenic Endothelium. <i>PLoS ONE</i> , 2012, 7, e51109.	1.1	23
120	Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation. <i>Modern Pathology</i> , 2003, 16, 886-892.	2.9	22
121	The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1796, 27-32.	3.3	22
122	Definition of miRNAs Expression Profile in Glioblastoma Samples: The Relevance of Non-Neoplastic Brain Reference. <i>PLoS ONE</i> , 2013, 8, e55314.	1.1	22
123	Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status. <i>Oncotarget</i> , 2018, 9, 1114-1129.	0.8	22
124	Circulating perivascular progenitors: A target of PDGFR inhibition. <i>International Journal of Cancer</i> , 2011, 129, 1344-1350.	2.3	21
125	Platelet Concentrates Stored in Synthetic Medium after Filtration. <i>Vox Sanguinis</i> , 1992, 62, 82-86.	0.7	20
126	Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. <i>Modern Pathology</i> , 2004, 17, 1513-1520.	2.9	20



#	ARTICLE	IF	CITATIONS
127	Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. <i>European Journal of Haematology</i> , 2004, 72, 264-267.	1.1	20
128	If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. <i>BMC Cancer</i> , 2010, 10, 644.	1.1	20
129	Adipose tissue and breast cancer progression: A link between metabolism and cancer. <i>Breast</i> , 2013, 22, S48-S49.	0.9	20
130	A new "two step"™ procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation. <i>Bone Marrow Transplantation</i> , 1997, 19, 615-619.	1.3	19
131	Cell cycle regulators in multiple myeloma: Prognostic implications of p53 nuclear accumulation. <i>Human Pathology</i> , 2003, 34, 41-47.	1.1	19
132	Platelet Concentrates Stored in Synthetic Medium after Filtration. <i>Vox Sanguinis</i> , 1992, 62, 82-86.	0.7	19
133	Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. <i>British Journal of Haematology</i> , 2003, 120, 695-698.	1.2	18
134	Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6039-6046.	3.2	18
135	On the Origin and Nature of Elevated Levels of Circulating Endothelial Cells After Treatment With a Vascular Disrupting Agent. <i>Journal of Clinical Oncology</i> , 2006, 24, 4040-4040.	0.8	18
136	Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. <i>Anti-Cancer Drugs</i> , 2009, 20, 197-203.	0.7	18
137	Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy. <i>Bone Marrow Transplantation</i> , 1997, 20, 167-169.	1.3	17
138	Adverse effects associated with extracorporeal photochemotherapy. <i>Transfusion</i> , 2000, 40, 121-121.	0.8	17
139	A Subpopulation of Circulating Endothelial Cells Express CD109 and is Enriched in the Blood of Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e114713.	1.1	17
140	Comparison of Platelet Activation and Membrane Glycoprotein Ib and IIb/IIIa Expression after Filtration through Three Different Leukocyte Removal Filters. <i>Vox Sanguinis</i> , 1990, 59, 201-204.	0.7	16
141	Leukocyte-Poor Blood Components: A Purer and Safer Transfusion Product for Recipients?. <i>Transfusion Medicine Reviews</i> , 1990, 4, 19-23.	0.9	16
142	Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. <i>International Journal of Cancer</i> , 2004, 112, 71-77.	2.3	16
143	Circulating Endothelial Progenitor Cells. <i>New England Journal of Medicine</i> , 2005, 353, 2613-2616.	13.9	16
144	Sex-related efficiency in NSG mouse engraftment. <i>Blood</i> , 2010, 116, 2616-2617.	0.6	16

#	ARTICLE	IF	CITATIONS
145	Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 95-101.	2.7	15
146	Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype. <i>British Journal of Haematology</i> , 2009, 144, 803-805.	1.2	15
147	Obesity, proinflammatory mediators, adipose tissue progenitors, and breast cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 545-550.	1.1	15
148	SP4, a Novel Anti-Cyclin D1 Rabbit Monoclonal Antibody, Is a Highly Sensitive Probe for Identifying Mantle Cell Lymphomas Bearing the t(11;14)(q13;q32) Translocation. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005, 13, 318-322.	0.6	14
149	The prevalence and clinical implications of c-kit expression in plasma cell myeloma. <i>Histopathology</i> , 2006, 48, 529-535.	1.6	14
150	Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells. <i>Frontiers in Oncology</i> , 2020, 10, 1225.	1.3	14
151	Circulating Endothelial Cells and Circulating Endothelial Progenitors. <i>Recent Results in Cancer Research</i> , 2012, 195, 163-170.	1.8	14
152	Mechanisms of obesity in the development of breast cancer. <i>Discovery Medicine</i> , 2015, 20, 121-8.	0.5	14
153	The metabolism of cells regulates their sensitivity to NK cells depending on p53 status. <i>Scientific Reports</i> , 2022, 12, 3234.	1.6	14
154	Strategies to Investigate Circulating Endothelial Cells in Cancer. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003, 33, 503-506.	0.5	13
155	Circulating endothelial cells as biomarkers for angiogenesis in tumor progression. <i>Frontiers in Bioscience - Scholar</i> , 2009, S1, 304-318.	0.8	13
156	Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-8.	3.8	13
157	Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. <i>Breast</i> , 2015, 24, 263-271.	0.9	13
158	Characterization of Cancer Stem Cells. <i>Methods in Molecular Biology</i> , 2016, 1464, 49-62.	0.4	13
159	Platelet concentrates prepared from pooled buffy-coats and stored in a glucose-free crystalloid medium. The Milan experience. <i>Transfusion Science</i> , 1990, 11, 357-362.	0.6	12
160	The effect of interleukin-12 in ex-vivo expansion of human haemopoietic progenitors. <i>British Journal of Haematology</i> , 1995, 90, 935-938.	1.2	12
161	Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34 <sup>+</sup> human stem cells. <i>British Journal of Haematology</i> , 2003, 123, 720-729.	1.2	12
162	Hepatocyte-conditioned medium sustains endothelial differentiation of human hematopoietic-endothelial progenitors. <i>Hepatology</i> , 2007, 45, 1218-1228.	3.6	12

#	ARTICLE	IF	CITATIONS
163	Circulating Endothelial Cell Number and Viability Are Reduced by Exposure to High Altitude. Endothelium: Journal of Endothelial Cell Research, 2008, 15, 53-58.	1.7	12
164	Cellular and soluble markers of tumor angiogenesis: From patient selection to the identification of the most appropriate postresistance therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 131-137.	3.3	12
165	Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. Leukemia Research, 2010, 34, 454-457.	0.4	12
166	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. Haematologica, 2020, 105, 2420-2431.	1.7	12
167	Platelet concentrates from buffy coats: Improved conditions for preparation and evaluation in routine clinical use. Transfusion Science, 1993, 14, 41-46.	0.6	11
168	Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). Scientific Reports, 2022, 12, 1341.	1.6	11
169	PLATELET QUALITY AND REDUCTION OF HLA EXPRESSION IN ACID-TREATED PLATELET CONCENTRATES. British Journal of Haematology, 1993, 83, 525-527.	1.2	10
170	Contribution of endothelial precursors of adipose tissue to breast cancer: Progression-link with fat graft for reconstructive surgery. Annales D'Endocrinologie, 2013, 74, 106-107.	0.6	10
171	Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai. Ecancermedicalscience, 2016, 10, 689.	0.6	10
172	A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies. Cell Death Discovery, 2022, 8, 106.	2.0	10
173	Safety, Tolerability and Biological Effects of Long-Term Metronomic Administration of Non-Cytotoxic Anti-Angiogenic Agents. Oncology, 2009, 77, 358-365.	0.9	9
174	Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer. Cancer Biology and Therapy, 2010, 10, 682-685.	1.5	9
175	Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly(ADP-ribose) polymerase inhibitors: A single-center experience. International Journal of Cancer, 2021, 148, 170-177.	2.3	9
176	Evaluation of Circulating Endothelial Precursor Cells in Cancer Patients. Methods in Molecular Biology, 2012, 904, 165-172.	0.4	9
177	Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization. Annals of Oncology, 1998, 9, 913-916.	0.6	8
178	Peripheral T-lymphocyte subsets in patients treated with Rituximab-Chlorambucil combination therapy for indolent NHL. Annals of Hematology, 2006, 85, 813-814.	0.8	8
179	The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification. Current Pharmaceutical Design, 2008, 14, 3780-3789.	0.9	8
180	Simultaneous characterization of progenitor cell compartments in adult human liver. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 31-40.	1.1	8

#	ARTICLE	IF	CITATIONS
181	Identifying Drug Repurposing Opportunities in Oncology. Cancer Journal (Sudbury, Mass ), 2019, 25, 82-87.	1.0	8
182	Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood, 2000, 96, 282-287.	0.6	8
183	GM-CSF promotes a supportive adipose and lung microenvironment in metastatic breast cancer. Oncoscience, 2017, 4, 126-127.	0.9	8
184	Umbilical Cord Blood Banking: Evaluation of the Collection Procedure and of CFU-GM Content. Stem Cells and Development, 1993, 2, 233-234.	1.0	7
185	Placental-Blood Transplantation. New England Journal of Medicine, 1997, 336, 68-70.	13.9	7
186	Idarubicin Containing Regimen in Multiple Myeloma: Preliminary Results of a Pilot Study Using a Modified "TANDEM" Transplant Program. Leukemia and Lymphoma, 2003, 44, 299-302.	0.6	7
187	Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. European Journal of Cancer, 2019, 122, 22-41.	1.3	7
188	The Dual Role of Innate Lymphoid and Natural Killer Cells in Cancer. from Phenotype to Single-Cell Transcriptomics, Functions and Clinical Uses. Cancers, 2021, 13, 5042.	1.7	7
189	Hematological disorders after salvage <sc>PARPi</sc> treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes. International Journal of Cancer, 2022, 151, 1791-1803.	2.3	7
190	Effects of storage temperature and time on cord blood progenitor cells. Transfusion, 1998, 38, 615-617.	0.8	6
191	Biomarkers of cancer angioprevention for clinical studies. Ecancermedicalscience, 2015, 9, 600.	0.6	6
192	Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens. Current Medicinal Chemistry, 2021, 28, 2114-2136.	1.2	6
193	Cellular and Molecular Players in the Interplay between Adipose Tissue and Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 1359.	1.8	5
194	Plasma levels of IL-8 and g-CSF in high-grade gliomas treated with bevacizumab.. Journal of Clinical Oncology, 2012, 30, 2083-2083.	0.8	5
195	Roles of obesity in the development and progression of breast cancer. Discovery Medicine, 2017, 24, 183-190.	0.5	5
196	STORAGE IN SYNTHETIC MEDIUM AND LEUKO&Ecircuml;E DEPLETION OF PLATELET CONCENTRATES. Vox Sanguinis, 1994, 67, 155-158.	0.7	4
197	Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology. Breast, 2009, 18, S48-S50.	0.9	4
198	Circulating endothelial cells as biomarkers for patients receiving bevacizumab. Lancet Oncology, The, 2011, 12, 217-218.	5.1	4

#	ARTICLE	IF	CITATIONS
199	Lenalidomide for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 367, 573-575.	13.9	4
200	On the clinical relevance of circulating endothelial cells and platelets in prostate cancer. <i>British Journal of Cancer</i> , 2013, 108, 1387-1387.	2.9	4
201	A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition. <i>EBioMedicine</i> , 2016, 10, 13-14.	2.7	4
202	Efficacy of venetoclax based salvage chemotherapy followed by "Minimal Residual Disease driven" venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2277-2279.	0.6	4
203	Anti-angiogenesis in cancer; met and unmet goals - an interview with Robert Kerbel. <i>International Journal of Developmental Biology</i> , 2011, 55, 395-398.	0.3	4
204	Gene Transfer-Mediated Generation of Drug-Resistant Hemopoiesis. <i>Leukemia and Lymphoma</i> , 1996, 21, 17-23.	0.6	3
205	Mosaic tumour blood vessels and high-dose chemotherapy for breast cancer. <i>Lancet Oncology</i> , The, 2001, 2, 595.	5.1	3
206	A "two-hit" (chemo)therapy to improve checkpoint inhibition in cancer. <i>Oncoscience</i> , 2021, 8, 55-57.	0.9	3
207	New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies. <i>Life</i> , 2021, 11, 1131.	1.1	3
208	Extracellular UTP Affects In Vitro Migration and In Vivo Homing and Engraftment of CD34+ Hematopoietic Stem Cells.. <i>Blood</i> , 2004, 104, 4122-4122.	0.6	3
209	Short- and long-term safety of the 2 × 10 <sup>6</sup> CD34+ cells/kg threshold for hematopoietic reconstitution after high-dose chemotherapy and peripheral blood progenitor cell support. <i>Annals of Oncology</i> , 2002, 13, 983-984.	0.6	2
210	Response to anti-angiogenesis: An ever changing feature. <i>Breast</i> , 2011, 20, S61-S62.	0.9	2
211	Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma " a case report. <i>Scientific Reports</i> , 2015, 5, 14829.	1.6	2
212	Desperately seeking   Models to find the right partner and the best use for checkpoint inhibitors. <i>British Journal of Cancer</i> , 2019, 120, 139-140.	2.9	2
213	Plant TDP1 (Tyrosyl-DNA Phosphodiesterase 1): A Phylogenetic Perspective and Gene Expression Data Mining. <i>Genes</i> , 2020, 11, 1465.	1.0	2
214	Metronomic Chemotherapy in Breast Cancers. , 2014, , 93-110.		2
215	SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial. <i>Blood</i> , 2021, 138, 3436-3436.	0.6	2
216	The Risk of Acquiring Transfusion-Transmissible Infections. <i>Vox Sanguinis</i> , 1988, 55, 186-187.	0.7	1

#	ARTICLE	IF	CITATIONS
217	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. <i>Leukemia Research</i> , 2008, 32, 1628-1632.	0.4	1
218	Quantification of Circulating Endothelial Cells by Flow Cytometry. <i>Clinical Cancer Research</i> , 2009, 15, 3640-3640.	3.2	1
219	Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies. <i>Cancers</i> , 2010, 2, 1027-1039.	1.7	1
220	Lung Cancer Onset in Wild Type Mice Following Bone Marrow Reconstitution with krasv12 Cells. <i>Scientific Reports</i> , 2015, 5, 13047.	1.6	1
221	P2.01-044 Baseline Peripheral Blood Cell Subsets Associated with Survival Outcomes in Advanced NSCLC Treated with Nivolumab in Second-Line Setting. <i>Journal of Thoracic Oncology</i> , 2017, 12, S812.	0.5	1
222	Human acute leukemia cells injected in NOD/LtSz-scid/IL-2R $\beta$ null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. , 2008, 123, 2222.		1
223	REPLY TO GUNSILIUS ET AL. <i>British Journal of Haematology</i> , 2000, 108, 662-663.	1.2	0
224	AGF will make you blush. <i>Blood</i> , 2004, 103, 3610-3611.	0.6	0
225	Targeting VE-cadherin (while naked, and not engaged). <i>Blood</i> , 2005, 105, 4157-4157.	0.6	0
226	About CD45 $^+$ /CD31 $^+$ /CD105 $^+$ Circulating Cells in Patients with Gynecologic Malignancies Letter. <i>Clinical Cancer Research</i> , 2014, 20, 1393-1393.	3.2	0
227	Lessons from the first cancer symposium on angiogenesis in gastric cancer. <i>Ecancermedalscience</i> , 2015, 9, 553.	0.6	0
228	Abstract 1653: A single-cell atlas of the effect of chemotherapeutics over intratumoral immune cells reveals that combining an alkylating agent and a vinca alkaloid can activate antigen presenting cells and increase tcf1 $^+$ stem-like CD8 $^+$ T-cells, thus improving anti-PD-1 efficacy in triple negative breast cancer and lymphoma. , 2021, , ,		0
229	Lymphoma Cell Detection and Follow-Up in the Rituximab Era: Concordance between Flow Cytometry, Qualitative/Quantitative PCR and FISH in the Marrow and Blood from 647 Patients.. <i>Blood</i> , 2004, 104, 1376-1376.	0.6	0
230	Prognostic Value of BCL2 Determination in Follicular NHL Patients Treated with Alkylating Containing Regimen Alone or in Combination with Rituximab.. <i>Blood</i> , 2004, 104, 4629-4629.	0.6	0
231	In Vitro and In Vivo Induction of Human Hematopoietic Stem Cell Migration by Extracellular UTP.. <i>Blood</i> , 2005, 106, 1730-1730.	0.6	0
232	Comparison of Three Different NOD/SCID-Related Strains in Preclinical Models of Acute Leukemia.. <i>Blood</i> , 2006, 108, 2361-2361.	0.6	0
233	Continuous Immuno-Chemotherapy Followed by High Dose and Autologous Cell Transplantation May Improve the Event-Free-Survival in Mantle Cell Lymphoma Patients. Experience at the European Institute of Oncology in Milan.. <i>Blood</i> , 2007, 110, 5116-5116.	0.6	0
234	Taxanes Induce a Rapid Mobilization of Different Populations of Circulating Endothelial Progenitors by SDF-1 Modulation in Cancer Patients.. <i>Blood</i> , 2008, 112, 1885-1885.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Molecular and Functional Analysis of Stem Cell Compartment of Chronic Myelogenous Leukemia Reveals the Presence of a CD34 <sup>hi</sup> cell Population with Intrinsic Resistance to IMATINIB Treatment. Blood, 2008, 112, 4221-4221.	0.6	0
236	IgG Antibodies against Human Cytomegalovirus Late Protein UL94 in the Pathogenesis of Scleroderma-Like Skin Lesions in Chronic Graft Versus Host Disease. Blood, 2008, 112, 1169-1169.	0.6	0
237	Impact of Endothelial Progenitor Cells on Tumor Angiogenesis and Outcome of Antiangiogenic Therapy: New Perspectives on an Ongoing Controversy. , 2010, , 257-273.		0
238	CD45-CD34+ Endothelial Progenitor Cells (EPCs) from Human Adipose Tissue Promote Tumor Growth and Metastases. Blood, 2011, 118, 2208-2208.	0.6	0
239	Mature Circulating Endothelial Cells and Progenitors in Patients with Chronic Gvhd. Blood, 2011, 118, 4700-4700.	0.6	0
240	Trafficking of Cells from Adipose Tissue to Tumor Microenvironment. , 2013, , 147-163.		0
241	P2X7 Receptor Activation By ATP As Target of Novel Therapies in Acute Myeloid Leukemia. Blood, 2015, 126, 3684-3684.	0.6	0
242	A Cellular Therapy with Haploidentical Peripheral Hematopoietic STEM CELL Transplantation MAY be a Therapeutic Option in Patients with Relapsed Lymphoma with Chemorefractory Disease. Blood, 2018, 132, 2189-2189.	0.6	0
243	Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features. Blood, 2019, 134, 5414-5414.	0.6	0
244	Metronomic Antiangiogenic Chemotherapy: Questions and Answers. , 2008, , 593-607.		0
245	Surrogate Markers of Angiogenesis. , 2008, , 795-808.		0